Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Takemura K, Lemelin A, Ernst M, Wells C, Basappa N, Szabados B, Powles T, Davis I, Wood L, Kapoor A, McKay R, Lee J, Meza L, Pal S, Donskov F, Yuasa T, Beuselinck B, Gebrael G, Choueiri T, Heng D. Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2023, 41: 600-600. DOI: 10.1200/jco.2023.41.6_suppl.600.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumFirst-line therapyRenal cell carcinomaAssociated with longer OSAnti-VEGF monotherapyAnti-VEGFBrain metastasesOutcomes of patientsBaseline patient characteristicsStable diseaseComplete responsePartial responseOverall survivalCombination therapyStereotactic radiosurgeryLonger OSLocal therapyPatient characteristicsInitiation of first-line therapyBest overall responseWhole-brain radiotherapyCohort of patientsProportion of patientsCell carcinomaDisease sites